BRIEF published on 04/02/2026 at 09:58, 5 months 11 days ago DBV Technologies: Thresholds crossed by JP Morgan Voting Rights Actions Crossing Thresholds DBV Technologies JP Morgan
BRIEF published on 04/02/2026 at 09:54, 5 months 11 days ago Adage Capital Management crosses thresholds at DBV Technologies Voting Rights Crossing Thresholds DBV Technologies Subscription Vouchers Adage Capital Management
BRIEF published on 03/26/2026 at 22:24, 5 months 17 days ago DBV Technologies publishes its financial reports for 2025 AMF Financial Report DBV Technologies DRY VIASKIN®
BRIEF published on 03/26/2026 at 22:24, 5 months 17 days ago DBV Technologies Files 2025 Annual Report and Registration Document Financial Filing Annual Report Universal Registration Document Form 10-K DBV Technologies
PRESS RELEASE published on 03/26/2026 at 22:19, 5 months 17 days ago DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies files 2025 Annual Report on Form 10-K and Universal Registration Document with SEC and AMF. Company developing treatments for food allergies Annual Report Immunotherapy Form 10-K DBV Technologies Food Allergies
BRIEF published on 03/24/2026 at 21:35, 5 months 19 days ago DBV Technologies Joins CAC Mid 60 and SBF 120 Indices Biopharmaceutical SBF 120 DBV Technologies CAC Mid 60 VIASKIN®
BRIEF published on 03/24/2026 at 21:35, 5 months 19 days ago DBV Technologies joins the CAC Mid 60 and SBF 120 indices Euronext Paris SBF 120 DBV Technologies CAC Mid 60 Inclusion Indices
PRESS RELEASE published on 03/24/2026 at 21:30, 5 months 19 days ago DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review DBV Technologies joins CAC Mid 60 and SBF 120 indices on Euronext Paris, increasing visibility among investors. Company focuses on food allergy treatments using VIASKIN patch technology Euronext Paris SBF 120 DBV Technologies Food Allergies CAC Mid 60
BRIEF published on 03/04/2026 at 22:35, 6 months 8 days ago DBV Technologies Announces Participation in March Investor Conferences Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/04/2026 at 22:35, 6 months 8 days ago DBV Technologies will participate in investor conferences in March Investor Conferences Biopharmaceutical DBV Technologies March 2026 Citizens Life Sciences
Published on 09/12/2026 at 02:35, 1 day 18 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 22 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 23 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 4 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 3 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 13 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 22 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 22 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days 1 hour ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 14 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 3 days 1 hour ago Availability of the 2026 Interim Financial Report
